EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)

Adel Mandl, Ruizhe Chen, Satya Das, Jonathan R Strosberg, Anup Kasi, Bhavana Konda iD, Daneng Li iD, Timothy F Burns, Aman Chauhan, Kristen K Ciombor, Farshid Dayyani, Tanya Dorff iD und 9 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag140 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Adel Mandl und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, US…. Hauptthemen laut MEDLINE: Anilides, Pyridines, Carcinoma, Neuroendocrine, Ipilimumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Government, HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poorly differentiated neuroendocrine carcinomas (NECs) are aggressive malignancies with limited treatment options. The low activity of immune checkpoint inhibitors (ICI) is in part due to an immunosuppressive tumor microenvironment. We hypothesized that adding cabozantinib to dual ICIs may improve clinical outcomes for patients.

Methods

Patients with advanced or metastatic, poorly differentiated NECs, excluding small cell lung and Merkel cell carcinoma, who progressed on first-line systemic therapy enrolled on this Simon’s two-stage trial. Patients received cabozantinib 40 mg daily, 3 mg/kg nivolumab plus 1 mg/kg ipilimumab every 3 weeks for four cycles, followed by maintenance cabozantinib nivolumab. The primary endpoint was ORR.

Results

Of 17 patients enrolled, 16 were evaluable. ORR was 12.5% (2/16; 95%CI: 1.6%-38.3%), with 2 durable (27 and 17 months). Median PFS was 2.7 months (95%CI: 1.8-5.6 months). Grade 3-4 treatment-related adverse events occurred in 9 patients (56%). The most frequent grade ≥3 toxicities were elevated liver enzymes, fatigue, and hypertension. Only one patient discontinued treatment due to toxicity. The study was terminated after the first stage, as it did not meet the threshold for proceeding to stage 2.

Conclusion

Toxicities were consistent with the known safety profiles of cabozantinib and dual immune checkpoint blockade. Long-term responses were observed in a small subset of patients, but the study did not meet the prespecified efficacy threshold for continued accrual. ClinicalTrials.gov identifier NCT04079712

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesPyridinesCarcinoma, NeuroendocrineIpilimumabNivolumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedAdult

Stichwörter der Autor:innen

cabozantinibcheckpoint inhibitorsimmunotherapyipilimumabneuroendocrine carcinomanivolumabtyrosine kinase inhibitor

Substanzen

cabozantinibAnilidesPyridinesIpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Vanderbilt University Medical Center, Nashville, TN, USA.
  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • University of Kansas Cancer Center, Kansas City, KS, USA.
  • The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, OH, USA.
  • City of Hope National Medical Center, Duarte, CA, USA.

ORCID-Profile: Bhavana Konda, Daneng Li, Tanya Dorff, Vineeth Sukrithan, Stephen V Liu, Michael A Carducci, Jan H Beumer

Förderung

  • NCI NIH HHS
  • U.S. Government
  • HHS
  • NCI
  • Department of Health and Human Services

Zitieren

APA

Mandl, A., Chen, R., Das, S., Strosberg, J. R., Kasi, A., Konda, B., Li, D., Burns, T. F., Chauhan, A., Ciombor, K. K., Dayyani, F., Dorff, T., Ohr, J. P., Patel, B. B., Sukrithan, V., Soares, H. P., Chen, K., Liu, S. V., Tesfaye, A. A., …, & Beumer, J. H. (2026). Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). The Oncologist. https://doi.org/10.1093/oncolo/oyag140

Vancouver

Mandl A, Chen R, Das S, Strosberg JR, Kasi A, Konda B, et al. Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). The Oncologist. 2026. doi:10.1093/oncolo/oyag140

BibTeX
@article{Mandl2026,
  author = {Mandl, Adel and Chen, Ruizhe and Das, Satya and Strosberg, Jonathan R and Kasi, Anup and Konda, Bhavana and Li, Daneng and Burns, Timothy F and Chauhan, Aman and Ciombor, Kristen K and Dayyani, Farshid and Dorff, Tanya and Ohr, James P and Patel, Bhaumik B and Sukrithan, Vineeth and Soares, Heloisa P and Chen, Kang and Liu, Stephen V and Tesfaye, Anteneh A and Carducci, Michael A and Beumer, Jan H},
  title = {Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag140}
}
Kostenlos starten →